Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Status:
Active, not recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if ofatumumab can help to control
CLL/SLL that has not yet been treated. The safety of this drug will also be studied.